A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults
Status:
Completed
Trial end date:
2020-01-29
Target enrollment:
Participant gender:
Summary
This study is designed to assess 1) the effect of multiple doses of itraconazole (CYP3A4
inhibitor), rifampin (CYP3A4 inducer), and esomeprazole (pH modifier) on the pharmacokinetics
of a single oral dose of ABI-H2158, and 2) the effect of steady-state oral ABI-H2158 on the
pharmacokinetics of midazolam (sedative) and levonorgestrel/ethinyl estradiol (active oral
contraceptive) in healthy adult participants.